Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 16/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.54 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.50 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23416354 | 0.89 | ROCK2 (0.55) | NAMPTROCK2 | |
| SCHEMBL26573404 | 0.86 | ALDH1A1 (0.49) | NPC1RAB9ANAMPT | |
| SCHEMBL23416116 | 0.86 | NAMPT (0.49) | NPC1RAB9ANAMPTROCK2TAS1R3 | |
| SCHEMBL17184350 | 0.78 | NAMPT (0.56) | NPC1RAB9ANAMPT | |
| SCHEMBL9613309 | 0.77 | TDP1 (0.67) | NPC1RAB9A | |
| SCHEMBL25011217 | 0.77 | ROCK2 (0.52) | NAMPTROCK2 | |
| SCHEMBL23416352 | 0.76 | NAMPT (0.56) | NAMPTROCK2 | |
| SCHEMBL23416012 | 0.74 | NAMPT (0.50) | NAMPT | |
| SCHEMBL23416011 | 0.73 | TGM2 (0.59) | NAMPT | |
| SCHEMBL23416016 | 0.73 | NAMPT (0.52) | NPC1RAB9ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321086-A1 | METHODS AND MATERIALS FOR INHIBITING NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-10-12 | — | — | US | disclosed |
| US-20230041576-A1 | METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321086-A1 | METHODS AND MATERIALS FOR INHIBITING NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE ACTIVITY | NAMPT, NNMT, NAPRT | NPC1 615/4885RAB9A 2508/4885NAMPT 1/4885 |
| US-20230041576-A1 | METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY | NFKBIA, IKBKB, NFKB2 | NPC1 1530/4885RAB9A 2742/4885NAMPT 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.